11 sep: Danmark: Inflation fortsætter høj stigningstakt for anden måned i..
11 sep: Lundbeck/fmd: Unikt karrierespring får Kåre Schultz til at stoppe
11-09-2017 09:15:06

Principal Investigator Dr. James Gulley to Provide Presentation Entitled "Therapeutic Vaccines in Prostate Cancer" at the ESMO 2017 Congress

Relateret indhold
16 okt - 
Tirsdagens aktier: C25 satte rekord trods Genmab-nedtur
12 okt - 
Fredagens aktier: Pandora til tops i første C25-optur i..
12 okt - 
Fredagens aktier: Pandora spurtede frem i første optur ..
Relateret debat
21 okt - 
Flot arbejde - Respekt👍
21 okt - 
J&J og Bavarian Nordic er ikke så offentlige omkring de..
21 okt - 
Rekrutteringen til fase 1 forsøg med HPV vaccinen er på..

MADRID, September 11, 2017 - This morning at the European Society for Medical Oncology (ESMO) 2017 Congress, Dr. James Gulley, Chief, Genitourinary Malignancies Branch, Senior Investigator, Head, Immunotherapy Section, Director, Medical Oncology Service, CCR Office of the Clinical Director, NCI, and Principal Investigator on PROSPECT, the Phase 3 study of PROSTVAC, will provide a presentation entitled "Therapeutic Vaccines in Prostate Cancer", including several blinded observations of the ongoing PROSPECT Phase 3 study.

As part of the presentation Dr. Gulley will highlight the blinded Kaplan-Meier curve for overall survival (OS) in the PROSPECT study for all patients, active and placebo. Dr. Gulley will also show this blinded median OS broken down by various geographies.

As the PROSPECT study is still ongoing, with full data expected in 2017, the data presented today are preliminary and fully blinded to the company and investigators and as such, no firm conclusions can be drawn about the eventual outcome of the PROSPECT Phase 3 study.

Following this presentation, a copy of the slides presented by Dr. Gulley can be found by visiting www.bavarian-nordic.com under "Investors > Events & Presentations".

About the PROSPECT study

The PROSPECT study is a global randomized, double-blind, placebo-controlled study in patients with asymptomatic or minimally symptomatic mCRPC. The trial is being conducted under a Special Protocol Assessment agreement with the FDA. The primary objective of the study is to determine whether the overall survival of patients receiving PROSTVAC (with or without the addition of granulocyte macrophage colony-stimulating factor; GM-CSF), is superior to that of patients receiving placebo.

The study completed recruitment in January of 2015 with a final enrolment of 1,297 men.  Based on the dosing schedule of PROSTVAC, all men would have completed their course of therapy no later than June 2015.

Three pre-specified interim analyses of data have been integrated into the statistical plan to evaluate whether the trial should continue as planned, or potentially be stopped early for efficacy or futility. Two of these interim analyses have already occurred, with the conclusion that the study should continue without modification. The third interim analysis is expected to occur in September 2017 with final data expected in the fourth quarter of 2017.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases, based on the Company's live virus vaccine platform. Through long-standing collaborations, including a collaboration with the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for infectious diseases, including the non-replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for emergency use by the United States and other governments. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its strategic partner Janssen are developing an Ebola vaccine regimen, and therapeutic vaccines for HPV, HBV and HIV. Additionally, in collaboration with the National Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer immunotherapies, including PROSTVAC®, which is currently in Phase 3 clinical development for the treatment of advanced prostate cancer. The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.

Contacts

Rolf Sass Sørensen

Vice President Investor Relations (EU)

Tel: +45 61 77 47 43

Seth Lewis

Vice President Investor Relations (US)

Tel: +1 978 341 5271

Press Release

2017-09-11-en


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bavarian Nordic A/S via Globenewswire

Vedhæftet fil: 2017-09-11-en.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
21 okt
BAVA
J&J og Bavarian Nordic er ikke så offentlige omkring deres resultater med deres ebola-vaccine. Senes..
15
19 okt
BAVA
  Her er lidt unævnte nyheder som jeg har noteret mig den sidste uges tid.   Bava har gang i job søg..
7
18 okt
BAVA
Meget relevant artikel som jo netop viser den store værdi RSV kan have hvis den lykkes for Bavarian ..
3
19 okt
BAVA
Emission snart eller må man afhænder voucher til en slik?
2
18 okt
BAVA
Det er jo fakta - hvis du vil have adgang til relevante informationer må du betale for det, alt er j..
2
18 okt
BAVA
Har aktien:   https://borsen.dk/nyheder/virksomheder/artikel/1/370784/bavarian_nordic_efter_johnson_..
2
17 okt
BAVA
De sidste par år er der sat gang i forsøg i oktober og november - den 8/8 blev afrapporteret gode da..
2
17 okt
BAVA
1 Mia er meget meget optimistisk scenarium. Mig bekendt regner de kun med 500-800 Mio.
2
20 okt
BAVA
Nej de har masser af penge og patenter mm. De endelig ku sælge ud af hvis det kom dertil. Fatter ik ..
1
19 okt
BAVA
2,1 mia i kassen ved årsskiftet... det tror jeg ikke..
1

Aktier/tendens: Blandet åbning efter markant international vending

19-10-2018 08:28:05
Det tegner til en blandet start på det danske aktiemarked fredag morgen, hvor Danske Bank igen kan indtage en hovedrolle efter skandalen med hvidvask og efterfølgende gang i svingdøren på direktionsgangen, mens ledelseskaos spreder sig på første sal i Holmens Kanal.Torsdag endte C25-indekset 0,9 pct. højere i 1055,38, mens den positive stemning i Europa stille og roligt fortog sig, særligt efter a..

DSV/Nykredit: Høj vækst kan være kortsigtet effekt af handelskrig

18-10-2018 10:11:03
Der var usædvanligt høje vækstrater hos DSV's konkurrent Kuehne + Nagel, da schweizerne aflagde sit regnskab for tredje kvartal torsdag morgen.Selskabet skriver selv, at det klarer sig langt bedre end markedet, men spørgsmålet er, om den store fremgang også er en kortsigtet effekt af handelskrigen, der har fået især amerikanske virksomheder til at skynde sig med at få importeret fra USA før toldst..

Banknordik opjusterer takket være sunde kunder

18-10-2018 08:26:15
Banknordiks kunder har det godt, og det giver lavere nedskrivninger for banken, der derfor opjusterer sine forventninger til 2018.Faktisk har nedskrivningerne været på et niveau, hvor der netto har været tocifrede millionoverskud på den post i alle tre kvartaler hidtil i år.Det fortæller Banknordik i en foreløbig regnskabsmeddelelse torsdag morgen.- Årsagen til opjusteringen af forventningerne til..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Bavarian Nordic A/S 163,40 -2,6% Fald i aktiekurs
Bavarian Nordic Ord Shs 163,40 -2,6% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Berlingske Media 2018  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
22. oktober 2018 02:51:40
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20181021.1 - EUROWEB6 - 2018-10-22 02:51:40 - 2018-10-22 02:51:40 - 1 - Website: OKAY